BioMarin All Set For Hemophilia Gene Therapy Approval, But Is It Overestimating Demand?

Gearing Up For August Approval

 
• By Andrew McConaghie

Analysts forecast a slow climb towards peak sales of $2bn – but competitors could erode that figure.

Biomarin
BioMarin needs to persuade payers that a $2-3m price tag for gene therapy is good value compared to conventional therapy • Source: BioMarin

More from Business

More from Scrip